Related Experiment Video
Updated: May 2, 2026
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis
H Tanaka1, T Aizawa2, S Watanabe2
1Department of Pediatrics, Hirosaki University Hospital Department of School Health Science, Faculty of Education, Hirosaki University hirotana@cc.hirosaki-u.ac.jp.
Insights
Multitarget therapy using mizoribine, tacrolimus, and prednisolone shows promise for treating pediatric lupus nephritis (LN). This approach led to significant improvements in patient outcomes with no serious adverse events observed.
Area of Science:
- Pediatric Nephrology
- Autoimmune Diseases
- Immunology
Background:
- Pediatric lupus nephritis (LN) management has advanced, yet more effective and less toxic treatments are needed.
- Optimal control of pediatric-onset LN remains a challenge, necessitating innovative therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy and safety of a multitarget induction therapy for pediatric-onset lupus nephritis.
- To assess treatment outcomes in children with biopsy-proven LN receiving a combination of mizoribine, tacrolimus, and prednisolone.
Main Methods:
- Seven children with biopsy-proven LN (class III/IV or V) received induction therapy with mizoribine (MZR), tacrolimus (Tac), and prednisolone (PDN).
- Patients were prospectively monitored for 32 months, with assessments at 3, 6, and 12 months.
- Post-treatment renal biopsies were performed in two patients with class III/IV LN.
Main Results:
- Significant improvements in urinary, serological, and clinical measures were observed within three months, persisting throughout the study period in most patients.
- Marked histologic improvement was confirmed in post-treatment renal biopsies of two patients.
- No serious adverse events were reported during the treatment course.
Conclusions:
- Multitarget therapy represents a potentially attractive treatment option for pediatric-onset lupus nephritis.
- Further research with larger patient cohorts is warranted to confirm these findings.
Background:
Recent advances in the management of lupus nephritis (LN) have also contributed to a favorable outcome in patients with pediatric-onset LN. Nevertheless, we believe that a more effective and less toxic treatment is needed to attain optimal control of pediatric-onset LN.
Methods:
Seven consecutive children with biopsy-proven LN (four with class III/IV and three with class V) received multitarget induction therapy consisting of mizoribine (MZR), tacrolimus (Tac), and prednisolone (PDN). They were prospectively evaluated at three, six, and 12 months, and at the latest observation point after a mean period of 32 months. Post-treatment renal biopsy was performed in two patients with class III/IV.
Results:
Despite gradually tapering the dose of concomitantly administered PDN, a significant improvement compared with baseline values was observed in the urinary, serological, and clinical assessment measures even at three months of treatment, and the favorable changes persisted throughout the treatment period in most of the study participants except for one. In two patients who underwent post-treatment renal biopsy, a marked histologic improvement was confirmed. No serious adverse events were observed.
Conclusions:
Multitarget therapy may be an attractive option for the treatment of pediatric-onset LN. Further studies involving a larger number of patients are needed.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption